title: Association between the characteristics of metabolic syndrome and Alzheimer's disease.
abstract: Various epidemiological studies have shown that type 2 diabetes and metabolic syndrome are highly correlated with Alzheimer's disease (AD). Here, we sought to assess the impact of metabolic syndrome characteristics on the progression of AD. Five-week-old male, spontaneously hypertensive (n = 32) and Wistar Kyoto (abbreviated WKY; n = 8) rats were divided into 5 groups (each n = 8): WKY, hypertension (HTN), streptozotocin-induced diabetes (STZ), high-fat diet (HFD), and STZ + high-fat diet-induced diabetes mellitus (DM). All animals were sacrificed and samples of the blood, liver, and brain were collected for further biological analysis. During the 15-week period of induction, the STZ and DM groups (animals injected with low-dose STZ) had significantly higher fasting glucose levels; the HFD group had elevated insulin levels, but normal blood glucose levels. The HFD and DM groups had hypercholesterolemia and higher hepatic levels of triglycerides and cholesterol. Additionally, correlations between HFD and elevated brain amyloid-beta 42 (Aβ-42), hyperglycemia and down-regulation of brain insulin receptor, and serum Aβ-42 and hepatic triglyceride concentrations (r(2) = 0.41, p < 0.05) were observed. Serum C-reactive protein and malondialdehyde did not appear to have a significant influence on the association with biomarkers of AD. Thus, our study demonstrated that rats with characteristics of metabolic syndrome had a large number of biomarkers predicting AD; however, no relationship between traditional inflammatory and oxidative markers and AD was found. Further studies are necessary to prove that these findings in rats are relevant to AD processes in humans.
authors: Department of Nutrition, China Medical University, No.91 Hsueh-Shih Road, Taichung, Taiwan, 40402, Republic of China.
authors: Hui-Ting
authors: HT
authors: Yang
authors: Yi-Jing
authors: YJ
authors: Sheen
authors: Chuen-Der
authors: CD
authors: Kao
authors: Chin-An
authors: CA
authors: Chang
authors: Ya-Chun
authors: YC
authors: Hu
authors: Jiann-Liang
authors: JL
authors: Lin
mesh_terms: D000544:Alzheimer Disease / Q000150:complications* / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D001921:Brain / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000150:complications* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000378:metabolism; D018450:Disease Progression; D015536:Down-Regulation; D007328:Insulin / Q000097:blood; D008099:Liver / Q000378:metabolism; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications* / Q000378:metabolism; D010446:Peptide Fragments / Q000378:metabolism; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D011972:Receptor, Insulin / Q000378:metabolism
chemical_list: D016229:Amyloid beta-Peptides; D001786:Blood Glucose; D007328:Insulin; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D011972:Receptor, Insulin
references: Neurobiol Dis. 2006 Oct;24(1):114-27
references: 16899370
references: J Lipid Res. 2003 Aug;44(8):1423-30
references: 12837845
references: Lancet Neurol. 2008 Sep;7(9):812-26
references: 18667359
references: J Alzheimers Dis. 2006 Mar;9(1):13-33
references: 16627931
references: Curr Neuropharmacol. 2011 Dec;9(4):693-705
references: 22654727
references: Lipids. 2001 Nov;36(11):1283-7
references: 11795862
references: Dig Dis Sci. 2010 Apr;55(4):931-40
references: 19459046
references: Neurology. 2006 Sep 12;67(5):843-7
references: 16966548
references: Neuroendocrinology. 2009;90(4):383-90
references: 19672057
references: Neurosci Biobehav Rev. 2011 May;35(6):1397-409
references: 21392524
references: J Alzheimers Dis. 2006 Sep;10(1):89-109
references: 16988486
references: Mol Pharmacol. 2007 Oct;72(4):850-5
references: 17609417
references: Eur Rev Med Pharmacol Sci. 2012 Jul;16 Suppl 3:10-7
references: 22957413
references: J Clin Neurol. 2011 Mar;7(1):10-8
references: 21519521
references: Rejuvenation Res. 2012 Apr;15(2):217-21
references: 22533436
references: Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:197-210
references: 12432919
references: J Neurochem. 2006 Aug;98(4):1068-77
references: 16787414
references: Arch Neurol. 2008 Jun;65(6):776-85
references: 18541797
references: Lancet Neurol. 2006 Aug;5(8):655-60
references: 16857570
references: Diabetes Care. 2009 Jan;32(1):169-74
references: 18945929
references: Neurology. 2004 Sep 14;63(5):828-31
references: 15365131
references: Neurosci Biobehav Rev. 1994 Fall;18(3):397-401
references: 7984357
references: Arch Neurol. 2003 Jul;60(7):958-64
references: 12873852
references: Pharmacol Rep. 2011;63(4):956-66
references: 22001983
references: Am J Pathol. 2003 Jan;162(1):313-9
references: 12507914
references: Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4162-7
references: 12634421
references: J Neurosci Res. 2011 Jun;89(6):808-14
references: 21374699
references: Brain. 2011 Mar;134(Pt 3):783-97
references: 21252113
references: Exp Diabetes Res. 2008;2008:704045
references: 19132099
references: Anal Biochem. 1978 May;86(1):271-8
references: 655387
references: Alzheimers Dement. 2010 Nov;6(6):440-7
references: 21044774
references: Altern Med Rev. 2009 Dec;14(4):373-9
references: 20030463